|
Market Closed -
Nasdaq
01:30:00 03/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 128.83 USD | +3.06% |
|
+0.55% | +30.43% |
| 01/09 | Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services | CI |
| 29/08 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
| Market Cap | 2.53TCr 2.19TCr 2.06TCr 1.88TCr 3.51TCr 2,39400Cr 3.53TCr 24TCr 9.46TCr 1,22400Cr 9.52TCr 9.31TCr 4,02000Cr | P/E 2026 * |
55.8x | P/E 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise Value | 2.11TCr 1.82TCr 1.72TCr 1.56TCr 2.92TCr 1,99400Cr 2.94TCr 20TCr 7.88TCr 1,02000Cr 7.93TCr 7.75TCr 3,34900Cr | EV / Sales 2026 * |
3.55x | EV / Sales 2027 * | 3.09x |
| Free-Float |
98.16% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Incyte Corporation
| 1 day | +3.06% | ||
| 1 week | +0.55% | ||
| Current month | +4.55% | ||
| 1 month | +8.78% | ||
| 3 months | +39.67% | ||
| 6 months | +28.78% | ||
| Current year | +30.43% |
| 1 week | 121.61 |  | 129.56 |
| 1 month | 115.77 | | 130.8 |
| Current year | 89.25 | | 132.6 |
| 1 year | 81.09 | | 132.6 |
| 3 years | 50.27 | | 132.6 |
| 5 years | 50.27 | | 132.6 |
| 10 years | 50.27 | | 153.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Meury
CEO | Chief Executive Officer | 58 | 26/06/2025 |
Suketu Upadhyay
DFI | Director of Finance/CFO | 57 | 04/05/2026 |
Pablo Cagnoni
PSD | President | 62 | 05/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Julian Baker
CHM | Chairman | 59 | 26/06/2025 |
| Director/Board Member | 72 | 20/01/2015 | |
Paul Clancy
BRD | Director/Board Member | 64 | 20/01/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/08/26 | Tax | EVP, Human Resources | -504 | 0.0002% | ||
| 19/08/26 | Sell | Chairperson | -10,801 | 0.0053% | ||
| 12/08/26 | Sell | Chairperson | -10,803 | 0.0053% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.06% | +0.55% | +49.84% | +103.59% | 2.53TCr | |
| +3.42% | +4.57% | +47.44% | +3.54% | 8.23TCr | |
| -2.24% | +0.77% | +523.44% | +37.90% | 6.16TCr | |
| +0.89% | +0.12% | -17.32% | -35.39% | 5.9TCr | |
| -1.25% | -5.30% | -1.98% | +33.18% | 5.12TCr | |
| +0.92% | -1.61% | +10.69% | +165.47% | 4.83TCr | |
| +3.07% | +0.72% | +59.47% | -16.38% | 3.19TCr | |
| +0.20% | +1.70% | -3.42% | +190.03% | 2.26TCr | |
| -0.52% | -3.11% | +60.78% | +115.64% | 1.66TCr | |
| -0.83% | -2.29% | -14.71% | +786.97% | 1.53TCr | |
| Average | +0.64% | -2.67% | +71.42% | +138.45% | 4.14TCr | |
| Weighted average by Cap. | +0.77% | -2.82% | +95.15% | +73.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 594.19Cr 512.61Cr 482.89Cr 439.97Cr 822.38Cr 56TCr 828.54Cr 5.72TCr 2.22TCr 29TCr 2.23TCr 2.18TCr 94TCr | 626.5Cr 540.48Cr 509.14Cr 463.89Cr 867.09Cr 59TCr 873.59Cr 6.03TCr 2.34TCr 30TCr 2.35TCr 2.3TCr 99TCr |
| Net income | 47Cr 40Cr 38Cr 34Cr 64Cr 4.4TCr 65Cr 448.19Cr 173.94Cr 2.25TCr 174.92Cr 171.1Cr 7.39TCr | 149.59Cr 129.05Cr 121.57Cr 110.76Cr 207.03Cr 14TCr 208.58Cr 1.44TCr 558.55Cr 7.22TCr 561.71Cr 549.43Cr 24TCr |
| Net Debt | -422.97Cr -364.89Cr -343.74Cr -313.19Cr -585.4Cr -40TCr -589.79Cr -4.07TCr -1.58TCr -20TCr -1.59TCr -1.55TCr -67TCr | -599.09Cr -516.83Cr -486.87Cr -443.6Cr -829.15Cr -57TCr -835.37Cr -5.76TCr -2.24TCr -29TCr -2.25TCr -2.2TCr -95TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | $128.83 | +3.06% | 23,24,073 |
| 01/26/01 | $125.01 | +1.45% | 11,91,993 |
| 31/26/31 | $123.22 | -0.92% | 14,83,195 |
| 28/26/28 | $124.37 | -2.64% | 12,15,069 |
| 27/26/27 | $127.74 | -0.30% | 7,00,682 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- INCY Stock
Select your edition
All financial news and data tailored to specific country editions
